Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells

International Journal of Biological Sciences

Volumn 8, Issue 1, 2011, Pages 15-29

  Wachter, Julia ^a   Neureiter, Daniel ^a   Alinger, Beate ^a   Pichler, Martin ^b   Fuereder, Julia ^a   Oberdanner, Christian ^c   Fazio, Pietro Di ^d   Ocker, Matthias ^d   Berr, Frieder ^a   Kiesslich, Tobias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c TECAN Austria   (Austria)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apoptosis; Biliary Tract Cancer; Cytotoxicity; Pharmacological inhibition; Wnt pathway

Indexed keywords

EID: 81255189044     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.8.15     Document Type: Article

References (50)

1. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997; 11: 3286-3305.
2. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006; 45: 375-388.
3. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999; 96: 5522-5527.
4. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362: 205-209.
5. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009; 28: 151-166.
6. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007; 19: 150-158.
7. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006; 5: 997-1014.
8. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005; 128: 1655-1667.
9. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
10. Kiesslich T, Neureiter D, Wolkersdorfer GW, et al. Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncol. 2010; 6: 1925-1936.
11. Hopfner M, Schuppan D, Scherubl H. Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol. 2008; 14: 7021-7032.
12. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003; 129: 199-221.
13. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281: 22429-22433.
14. Kiesslich T, Alinger B, Wolkersdorfer GW, et al. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol. 2010; 36: 49-58.
15. Ashida K, Terada T, Kitamura Y, et al. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology. 1998; 27: 974-982.
16. Sugimachi K, Taguchi K, Aishima S, et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol. 2001; 14: 900-905.
17. Tokumoto N, Ikeda S, Ishizaki Y, et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005; 27: 973-980.
18. Pagano MA, Meggio F, Ruzzene M, et al. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun. 2004; 321: 1040-1044.
19. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008; 7: 521-529.
20. Gao Y, Wang HY. Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling. J Biol Chem. 2006; 281: 18394-18400.
21. Seldin DC, Landesman-Bollag E, Farago M, et al. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem. 2005; 274: 63-67.
22. Park CH, Chang JY, Hahm ER, et al. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 2005; 328: 227-234.
23. Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood. 2008; 112: 5171-5179.
24. Shan BE, Wang MX, Li RQ. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009; 27: 604-612.
25. Kiesslich T, Neureiter D, Alinger B, et al. Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci. 2010; 9: 734-743.
26. Czekanska EM. Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol Biol. 2011; 740: 27-32.
27. Cai C, Rodepeter FR, Rossmann A, et al. Nef from SIV(mac239) decreases proliferation and migration of adenoid-cystic carcinoma cells and inhibits angiogenesis. Oral Oncol. 2011; 47: 847-854.
28. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003; 425: 846-851.
29. Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008; 20: 119-125.
30. [Internet] Nusse R. The Wnt Homepage http://www.stanford.edu/group/nusselab/cgi-bin/wnt/
31. Behrens J, Lustig B. The Wnt connection to tumorigenesis. Int J Dev Biol. 2004; 48: 477-487.
32. Miranda-Carboni GA, Krum SA, Yee K, et al. A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev. 2008; 22: 3121-3134.
33. Yde CW, Frogne T, Lykkesfeldt AE, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett. 2007; 256: 229-237.
34. Chiu WT, Shen SC, Chow JM, et al. Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation. Neurobiol Dis. 2010; 37: 118-129.
35. Boly R, Gras T, Lamkami T, et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol. 2011; 38: 833-842.
36. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2008; 1784: 33-47.
37. Shih YW, Wu PF, Lee YC, et al. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. J Agric Food Chem. 2009; 57: 3490-3499.
38. Siegelin MD, Gaiser T, Habel A, et al. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett. 2009; 283: 230-238.
39. Kumamoto T, Fujii M, Hou DX. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem. 2009; 332: 33-41.
40. Lopez-Lazaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res. 2010; 696: 41-47.
41. Kumamoto T, Fujii M, Hou DX. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett. 2009; 275: 17-26.
42. Vaid M, Prasad R, Sun Q, et al. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One. 2011; 6:e23000.
43. Tapia JC, Torres VA, Rodriguez DA, et al. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A. 2006; 103: 15079-15084.
44. Plaetzer K, Kiesslich T, Krammer B, et al. Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT. Photochem Photobiol Sci. 2002; 1: 172-177.
45. Lee KW, Kang NJ, Rogozin EA, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007; 28: 1918-1927.
46. Kaminska B, Ellert-Miklaszewska A, Oberbek A, et al. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells. Int J Oncol. 2009; 35: 1091-1100.
47. Lawnicka H, Kowalewicz-Kulbat M, Sicinska P, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010; 340: 371-379.
48. Sass G, Klinger N, Sirma H, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011; 39: 433-442.
49. Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70: 10288-10298.
50. Kiesslich T, Berr F, Alinger B, et al. Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology. Curr Pharm Biotechnol. 2011; epub.